GSK Gets Renewed Invitation to Human Genome Sciences Strategic Review
16 June 2012 - 12:42AM
Dow Jones News
LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN)
Friday confirmed that it has received a renewed invitation from
Human Genome Sciences (HGSI) to participate in its strategic
alternatives review process which started in April, and said it is
continuing with its tender for the company.
MAIN FACTS:
-GSK continues to believe that participation in the process is
unnecessary given the company's offer is not conditioned on due
diligence or financing and can be completed expeditiously.
-Shares at 1405 GMT down 0.7%, at 1,449 pence valuing the
company at GBP72.6 billion.
-Write to Ed Ballard at ed.ballard@dowjones.com
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Apr 2024 to May 2024
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Human Genome Sciences, Inc. (MM) (NASDAQ): 0 recent articles
More Human Genome Sciences Inc. News Articles